Recent Finacing
Recent Raise
Targazyme develops clinical-grade fucosyltransferase enzymes and small-molecule cell-surface modifiers (TZ101/TZ102) for point-of-care ex vivo treatment of therapeutic cells to enhance Treg persistence and reduce GVHD.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor